BioNTech (NASDAQ:BNTX) has agreed to acquire its German rival CureVac (NASDAQ:CVAC) in an all-stock transaction worth nearly ...

The latest health news covers FDA's extended review of KalVista's drug, UroGen's new bladder cancer treatment approval, ...

BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal that combines two of the world's leaders in mRNA treatments.

Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...